Most health-tech ideas I see arrive with the technology already half-built. The founder has a clever algorithm, a sensor, a slick interface. What they often don't have is a clear-eyed answer to a harder question: whose problem does this actually solve, and does that person have the standing to buy, install, and sustain it?
That gap is where good ideas quietly die. So before anyone writes a line of production code, I push founders through validation as a discipline. Not a pitch rehearsal. Not a single customer survey. A sequence of risk reduction.
Contents
- Why Validation Starts Before the Prototype
- Define the Care Problem in the Workflow Where It Happens
- Find the Stakeholder Who Actually Feels the Pain
- Screen Regulatory, Privacy, and Evidence Requirements Early
- Run Discovery in Real Georgia Care and Commercial Settings
- Convert Validation Findings Into a Go/No-Go Matrix
- Scope and Limitations: What Early Validation Cannot Prove
- Academic Sources
Why Validation Starts Before the Prototype
A plausible technology is not a validated problem. I have watched teams spend a year engineering remote monitoring tools for a care gap that, on close inspection, no one in the workflow was paid or measured to close. The tech worked. The case for adoption never existed.
Think of validation as a staircase of falsifiable risks. Is the problem real? Does it hurt enough that someone acts? Can that someone approve a purchase? Will the product fit the workflow without breaking three others? Each step you skip is a risk you carry, silently, into your burn rate.
Georgia gives founders an unusually dense set of resources to test those risks against reality. You may be working within reach of academic research at the Georgia Institute of Technology, large hospital systems, rural care networks with real access challenges, logistics assets that touch healthcare delivery, and life-sciences commercialization support through the Georgia Research Alliance. The terrain is rich. The trick is using it to disprove your assumptions, not to confirm them.
Key Takeaway: Validation is risk reduction in sequence, not a one-time survey. Every assumption you leave untested becomes a cost you pay later.
Define the Care Problem in the Workflow Where It Happens
"Diagnostic support" is not a problem. It's a category. The problem lives in a specific moment: a nurse at shift change who can't tell whether a flagged result was already acted on, a care navigator who loses a patient between the discharge call and the follow-up that never gets booked.
So I ask founders to document the current state in plain language. Who notices the problem first? What triggers action? What tools are already in hand? Where do handoffs fail, and what consequence actually matters to the clinician, the administrator, the patient, or the payer?
On one engagement, the sequencing mattered more than I expected. We started at the handoff points—watching where information dropped, and only then mapped consequences backward to the originating trigger. An earlier instinct to lead with a broad survey got set aside; the survey would have averaged away the very moments where the failure lived. Structured interviews across three shifts gave us a sharper picture, and the problem statement came together within a couple of days of the site visit.
Clinical pain versus operational pain
Separate the two early, because they sell to different people. A product might improve patient experience, reduce staff burden, support compliance, accelerate a clinical decision, or improve visibility across sites. Those are not the same value proposition, and they rarely share the same budget line.
One detail kept us honest: workflow maps from urban academic centers showed different handoff failure modes than those recorded at rural sites. The same idea did not validate identically across both. That divergence is a finding, not a nuisance.
Find the Stakeholder Who Actually Feels the Pain
Here is the trap that catches the most founders. "The clinicians love it." Wonderful. The clinician is rarely the person who approves the budget, integrates the software, trains the staff, owns the data, or signs off on compliance.
In health-tech, those roles split across different people:
- User — the clinician or staff member who touches the tool daily.
- Buyer, the executive or department head who controls the budget.
- Implementer, the IT or operations team that has to make it work.
- Data owner, whoever is accountable for the patient information involved.
- Compliance reviewer, the gatekeeper for privacy and risk.
- Beneficiary, the patient or population who gains, but who may never see the product directly.
Map the incentives across all of them. A hospital executive weighs cost and risk. An employer health team weighs absenteeism and claims spend. A payer weighs outcomes against reimbursement. A community provider weighs whether they can sustain one more login. When their incentives pull in different directions, your adoption story has to account for it.
So enthusiasm from the user is a signal, not a verdict. Until you know who can approve, budget, integrate, train, and sustain the product, you have a fan—not a customer.
Screen Regulatory, Privacy, and Evidence Requirements Early
Regulatory screening is a validation task, not a cleanup job for after the engineers finish. The classification you fall into shapes your evidence burden, your timeline, and sometimes your entire business model. Discovering that after a build is an expensive way to learn.
Start by testing which category your product plausibly sits in:
- General wellness product
- Clinical decision support software
- Software as a medical device
- Connected device
- Diagnostic tool
- Data platform
- Care operations software
The honest answer is that classification depends on your intended use and the claims you make—not on the underlying code. Two products with similar architecture can land in different regulatory worlds because one claims to inform a diagnosis and the other claims only to organize information. Review whether your product may fall under device software guidance, and frame your claims deliberately. The FDA's device software functions guidance is the right starting reference for that question.
Warning: Your marketing language can change your regulatory category. Make claims you can support, and make them on purpose—not by accident in a pitch deck.
Privacy belongs in this same early pass. If your idea depends on patient data flowing between organizations, identify who owns that data and what consent and security obligations come attached before you assume access.
Run Discovery in Real Georgia Care and Commercial Settings
Discovery is fieldwork. You conduct structured interviews, observe the workflow where you're permitted, review the procurement constraints that govern any real purchase, and test whether anyone would actually join a pilot.
One choice shaped our results more than any other: we selected discovery environments by matching workflow density to available access windows, not by chasing institutional prestige. A well-connected academic center with no open window teaches you less than a community clinic that lets you watch a full intake. We also tested our interview prompts across two pilot rounds before the full rollout, which trimmed the questions that produced polite, useless answers.
Georgia offers a spread of settings worth approaching—without overstating any formal relationship: clinical simulation spaces, university research labs, hospital innovation offices, community clinics, rural provider networks, employer health teams, medical-device manufacturers, and logistics operators that touch healthcare delivery.
Interview prompts that earn real answers
- What happens before and after this workflow?
- What workaround do you use now?
- Who would object to changing it?
- What would make a pilot impossible?
- What evidence would your organization need before adoption?
That last question separated buyers fast. Evidence expectations diverged sharply between employer health programs and regional hospital procurement teams—the bar one accepted, the other waved off as anecdote. If you only interview one type, you'll calibrate your evidence plan to the wrong audience.
Pro Tip: Ask what happens before and after the workflow moment you care about. The adjacent steps usually hide the real adoption barriers.
Convert Validation Findings Into a Go/No-Go Matrix
Discovery generates a pile of notes. The job now is to turn that pile into a decision. I use a simple matrix that scores the idea across the dimensions that actually predict adoption.
Columns I keep on every version:
- Problem urgency
- User access
- Buyer clarity
- Workflow fit
- Regulatory exposure
- Data access
- Technical feasibility
- Evidence burden
- Reimbursement or budget pathway
- Implementation complexity
Score each honestly, and the path usually announces itself. The decision lands in one of five buckets:
- Proceed to prototype — the risks are understood and tolerable.
- Narrow the use case, one workflow validates cleanly; the rest don't yet.
- Seek a clinical or industry partner, you need access or credibility you can't build alone.
- Gather more evidence, the buyer's bar is clear but you haven't cleared it.
- Stop, the adoption barriers outweigh the opportunity.
That last category is the one founders resist and the one that saves the most money. A clean "no" returns your time and capital for the idea that deserves them.
Scope and Limitations: What Early Validation Cannot Prove
I want to be precise about what this process delivers, because it touches several authority domains—FDA device software context, privacy compliance, institutional review considerations, and evidence expectations, and it would be dishonest to imply it settles any of them.
Early validation does not prove clinical effectiveness. It does not grant regulatory clearance, secure reimbursement, confirm cybersecurity readiness, or guarantee procurement approval. We drew those scope boundaries deliberately, by listing the downstream activities that interviews simply cannot substitute for.
Discovery observations surface adoption signals; they leave formal clinical studies, quality-system documentation, and payer negotiations untouched. When your category requires those, validation tells you to plan for them—it does not perform them. The mapping work here reflects the Georgia settings sampled, and a different mix of sites could shift which barriers surface first.
So treat a strong validation result as permission to invest in the next, harder questions. Not as proof you've already answered them.
